MDGL - Tracking Baker Brothers Portfolio - Q4 2023 Update
2024-03-06 17:09:23 ET
Summary
- Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B.
- The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma.
- New stakes include Cerevel Therapeutics, while stake disposals include BioMarin Pharmaceutical.
This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 2/14/2024. The 13F portfolio value decreased from $17.35B to $8.79B. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. There are 21 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. The largest five stakes are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. They add up to ~72% of the portfolio. Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update for the fund’s moves during Q3 2023....
Tracking Baker Brothers Portfolio - Q4 2023 Update